Download Poster (1.7 MB)
❖ Uveal melanoma is the most common primary intraocular malignant tumor in adults.
❖ Up to half of all patients develop systemic metastases, with liver involvement in >90% of patients.1
❖ Various liver-directed, locoregional therapies (i.e. chemoembolization, immunoembolization, radioembolization, and ablation) have played a significant role in prolonging the lives of patients with metastatic uveal melanoma.2
❖ Elevated bilirubin levels are typically considered a relative contraindication for lobar hepatic arterial embolization treatment, given mainly the increased risk of precipitating hepatic failure.
❖ Gilbert's syndrome, also known as benign unconjugated hyperbilirubinemia, is a hereditary disorder of bilirubin conjugation. Gilbert’s syndrome leads to elevated levels of serum bilirubin, that do not truly reflect cholestasis or liver failure and therefore should not exclude patients from targeted embolization therapy.3
Poster presented at: World Conference on Interventional Oncology in Boston MA.
Safety of Lobar Hepatic Arterial Embolization in Metastatic Uveal Melanoma Patients with Underlying Gilbert's Disease
Oncology | Radiology
Feldstein, MD, David C.; Adamo, MD, Robert D.; Gonsalves, MD, FSIR, Carin F.; Eschelman, MS, FSIR, David J.; Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA; and Sato, MD, PhD, Takami, "Safety of Lobar Hepatic Arterial Embolization in Metastatic Uveal Melanoma Patients with Underlying Gilbert's Disease" (2016). Department of Medical Oncology Posters. 4.